Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA312
  • Published: 
  • Last updated: 

History

Multiple sclerosis (relapsing-remitting) - alemtuzumab: equality impact assessment - guidance development

Multiple sclerosis (relapsing-remitting) - alemtuzumab: final appraisal determination

Multiple sclerosis (relapsing-remitting) - alemtuzumab: appraisal consultation

Multiple sclerosis (relapsing-remitting) - alemtuzumab: equality impact assessment - scoping

Multiple sclerosis (relapsing-remitting) - alemtuzumab: response to consultee and commentator comments on the draft scope and provisional matrix (post-referral)

Multiple sclerosis (relapsing-remitting) - alemtuzumab: final matrix

Multiple sclerosis (relapsing-remitting) - alemtuzumab: final scope

Multiple sclerosis (relapsing-remitting) - alemtuzumab: draft scope for consultation (post-referral)

Multiple sclerosis (relapsing-remitting) - alemtuzumab: provisional matrix for consultation (post-referral)

Multiple sclerosis (relapsing-remitting) - alemtuzumab: draft scope - (pre referral)

Multiple sclerosis (relapsing-remitting) - alemtuzumab: provisional matrix - (pre referral)